

Prevention & Treatment of Hepatitis and Chronic Liver Disease

San Diego, CA October 14, 2023

Conference Location	DoubleTree San Diego – Hotel Circle 1515 Hotel Circle-South San Diego, CA 92108	Phone: (619) 881-6100 https://www.hilton.com/en/hotels/sancldt-doubletree-san-diego-hotel-circle
----------------------------	---	--

A special parking reduced rate of \$10 per day has been arranged for day guests.

Parking and Hotel Information	We have arranged for reduced rate for guest rooms of \$179 plus tax, Until September 27, Go to: https://www.hilton.com/en/book/reservation/deeplink/?ctyhoc=SANCLDT&groupCode=CDT90D&arrivaldate=2023-10-13&departuredate=2023-10-14&cid=OM,WW,HILTONLINK,EN,DirectLink&fromId=HILTONLINKDIRECT
--------------------------------------	---

Driving Directions	From San Diego International Airport – Take Interstate 5 - Northbound - Exit US 8 – East toward El Centro. Take Exit 4a- Hotel Circle. Turn Right (West) on Hotel Circle – South. The hotel will be on your right in 0.4 miles.
---------------------------	---

Seminar Agenda and Syllabus Information	Registration begins at 7:15 a.m. in the Cabrillo Room Please check signage for any last-minute changes. The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi is available without charge.
--	---

Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
7:30 am	<i>Registration and View Exhibits</i>
8:00 am	Opening Comments and Pre-Test
8:20 am	Advances in the Screen and Treatment of HCV <ul style="list-style-type: none"> • Highlight of Pre-Lecture 1 • Screening and Treatment of HCV Clinical Cases and Discussion
9:05 am	Hepatitis B: Epidemiology, Natural History and Testing <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • Anti-viral therapies of HBV • The growing relationship between HBV and HDV
9:35 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> • Worldwide perspective and promising research studies • Real world outcome studies on HDV and HEV
10:05 am	<i>Break and View exhibits</i>
10:20 am	End Stage Liver Disease: Recap and Clinical Cases <ul style="list-style-type: none"> • A review of Pre-course lecture on end-stage liver disease • Clinical cases to illustrate HE and Thrombocytopenia
10:55 am	Hepatocellular Carcinoma(HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery

11:35 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • A case-based approach to HCC treatment • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC
12:10 pm	<i>Luncheon and Product Information Session</i>
12:55 pm	<i>Dessert and View Exhibits</i>
1:10 pm	Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
1:40 pm	Alcohol Associated Liver Disease <ul style="list-style-type: none"> • The growing prevalence of alcohol over-consumption and its impact on liver health • Warning signs and intervention in alcohol-associated hepatitis
2:10 pm	Fluid Management, Ascites and Hepatorenal Syndrome <ul style="list-style-type: none"> • The diagnosis and treatment of ascites • How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome New and emerging treatment approaches for of HRS
2:45 pm	<i>Break and View Exhibits</i>
3:00 pm	NAFLD and NASH: The new healthcare epidemic <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Fatty Liver Disease • The ‘unhealthy’ rise in Fatty Liver Disease in the US population and What can be done • Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy • Drugs in clinical development for NASH • NASH Diagnosis and Treatment cases
4:15 pm	Closing Comments, Post-test and Wrap-Up <ul style="list-style-type: none"> • Program adjourns at 4:30 pm
Post-program activities	Lecture 3 - SARS-CoV-2 and its Effect on the Liver – 45 minutes Lecture 4 - Overcoming barriers to liver health in special populations - 45 minutes

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

**CME
Information**

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1318. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME

**Your
Seminar
Faculty**




JULIO GUTIERREZ, MD, MS

Dr. Julio Gutierrez is a board certified hepatologist in practice since 2014. He is an expert in cirrhosis and the conditions that cause it including hepatitis C, fatty liver, autoimmune hepatitis, cholestatic disease, and metabolic disease.

He is board certified in liver transplant and is an expert at managing decompensated liver disease complications such as ascites and encephalopathy. He joined Scripps to assist in

efforts to increase access to liver related healthcare for patients in areas throughout San Diego and Southern California



JENNIFER AU, MD

Jennifer Au, MD, is a board-certified gastroenterologist and transplant hepatologist who specializes in liver disease, hepatocellular carcinoma, non-alcoholic fatty liver disease and liver transplantation. She has been practicing medicine since 2016 and is the director of the Scripps/MD Anderson hepatocellular carcinoma program.

Dr. Au graduated from Temple University School of Medicine and fulfilled an Internal Medicine residency at Thomas Jefferson University Hospital in Philadelphia. She has also completed two post-graduate fellowships – the first in Gastroenterology and Hepatology at Scripps Clinic in La Jolla, CA and the second in Transplant Hepatology at Albert Einstein Medical Center in Philadelphia.



LISA RICHARDS, FNP-BC, MSN

Lisa Richards is a board-certified Family Nurse Practitioner with the University of California San Diego Health System. She received her bachelor and Master of Science degree in nursing, magna cum laude, from the University of San Diego.

She has been in Hepatology for 20 years with expertise in NAFLD and NAFLD related research. She is the Assistant Director of Clinical Operations for the NAFLD Research Center. She is a member of the American Association for the Study of Liver Disease and awarded the distinction of Associate Fellow, which recognizes excellence and leadership within AASLD. Ms. Richards is very active in the field of Hepatology and is an international and national speaker.
